Gregory G Schwartz

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

J Wouter Jukema, Deepak L. Bhatt, Deepak L Bhatt, 2018, The New England journal of medicine.

Pharmacologic and Genetic Downregulation of Proprotein Convertase Subtilisin/Kexin Type 9 and Survival From Sepsis

L. Milani, B. Nordestgaard, K. Hveem, 2023, Critical care explorations.

Patients With High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit From Alirocumab Treatment in the ODYSSEY OUTCOMES Trial

G. Abecasis, E. Hagström, G. Yancopoulos, 2019, Circulation.